Stefan C. Weiss, MD FAAD has designed The Weiss Skin Institute with the capabilities to perform both Sponsor Initiated Phase 3 and Phase 4 clinical trials as well as Investigator Initiated studies. Dr. Weiss formerly served as the Senior Medical Director at Connetics Corporation a biotechnology company in Palo Alto, Calif. focused on the development of novel therapeutics for the treatment of dermatologic diseases. Under his medical leadership, three New Drug Applications (NDAs) were drafted and all three therapies have been approved by the FDA for use. In his role, he was responsible for oversight of protocol development, pharmacovigilance and data review. He conducted investigator meetings and addressed both protocol questions and protocol violations with investigators. Having spent nearly two years working in the pharmaceutical industry, he is able to collaborate effectively with the clinical development teams of both large and small pharmaceutical and biotechnology firms as he has a clear understanding of their needs. Dr. Weiss has a unique appreciation of the rigor required for a successful development program having been intimately involved on the industry side and will be able to fulfill the requirements of a phase 3 study protocol competently and expeditiously. For more information regarding Dr. Weiss’ credentials or to discuss with him a site initiation visit please contact the Weiss Skin Institute by telephone at 561-372-SKIN or by email at firstname.lastname@example.org.